FDA label 29a4fcab-bf85-5a81-e063-6394a90a62ba
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 4bff61ca-ac43-4b41-877b-3969474cd02c
- SPL ID
- 29a4fcab-bf85-5a81-e063-6394a90a62ba
- Version
- 7
- Effective date
- 2024-12-19
- Source export date
- 2026-11-13
- Source partition
- 6
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:20:41
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 29a4fcab-bf85-5a81-e063-6394a90a62ba | id | |
| spl set id | 4bff61ca-ac43-4b41-877b-3969474cd02c | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Life-threatening air or gas embolism has occurred with the use of spray devices employing a pressure regulator to administer EVICEL ® . This event appears to be related to the use of the spray device at pressures higher than recommended and/or at distances closer than recommended to the surface of the tissue ( 2.3 , 5.1 ) . Monitor changes in blood pressure, pulse, oxygen saturation and end-tidal CO 2 when spraying EVICEL ® because of the possibility of gas embolism ( 5.1 ) . To reduce the risk of potentially life-threatening gas embolism, spray EVICEL ® using only pressurized CO 2 gas at the pressures and distances recommended for the specific tips ( 2.3 ) . Use EVICEL ® spray application only if it is possible to accurately judge the spray distance, especially during endoscopic or laparoscopic procedures ( 2.3 , 4.4) . Prior to applying EVICEL ® , dry surface areas of the wound by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices) ( 2.3 ) . Prepare and administer EVICEL ® according to the instructions and with only devices recommended for this product ( 2.3 ) . May carry a risk of transmitting infectious agents e.g., viruses, the variant Creutzfeldt-Jakob disease (CJD) agent and, theoretically, the classic (CJD) agent ( 5.2 ) . 5.1 Application Precautions Excessive product application thickness may negatively interfere with the product's efficacy and the wound healing process. Apply EVICEL® as a thin layer. To reduce the risk of potentially life threatening air embolism, follow specific spray instructions for the pressure and distance from tissue recommended for each type of surgical procedure and length of application tip [see Dosage and Administration (2.2) ] . Spray EVICEL ® using pressurized CO 2 gas only. When using the Airless Spray Accessory and Laparoscopic Airless Spray Accessory (35 cm Rigid), the need for connection to an external CO 2 or other gas source has been eliminated. Use EVICEL ® spray application only if it is possible to accurately judge the distance from the spray tip to the tissue surface, especially during laparoscopic or endoscopic procedures. Monitor changes in blood pressure, pulse, oxygen saturation and end-tidal CO 2 when spraying EVICEL ® because of the possibility of gas embolism. Prior to applying EVICEL ® , dry surface areas of the wound by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices). 5.2 Infection Risk from Human Plasma EVICEL ® is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob (CJD) agent. There is also the possibility that unknown infectious agents may be present in such products. All infections thought by a physician to have been possibly transmitted by this product should be reported by the physician or other healthcare provider to ETHICON Customer Support Center at (877) 384-4266. The physician should discuss the risks and benefits of this product with the patient.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (0.5% of subjects) reported in clinical trials are peripheral edema, abdominal abscess, infection, hematoma, incision site hemorrhage, vascular graft occlusion, postoperative wound complication and decreased hemoglobin ( 6.1 ). The most common additional adverse reactions reported in postmarketing experience are, pyrexia, seroma, cardiac arrest, tachycardia, pulmonary embolism, dyspnea, and urticaria ( 6.2 ). The most common adverse reactions reported in clinical trials are peripheral edema, abdominal abscess, infection, hematoma, incision site hemorrhage, vascular graft occlusion, postoperative wound complication and decreased hemoglobin ( 6.1 ) . The most common additional adverse reactions reported in postmarketing experience are, pyrexia, seroma, cardiac arrest, tachycardia, pulmonary embolism, dyspnea, and urticaria ( 6.2 ) . To report SUSPECTED ADVERSE REACTIONS, contact ETHICON Customer Support Center at (877) 384-4266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Clinical trials are conducted under widely varying conditions; therefore adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Vascular Surgery In a controlled study involving 147 subjects undergoing vascular grafting procedures (75 treated with EVICEL ® and 72 controls), nine subjects experienced 12 adverse reactions including graft or staphylococcal infection, hematoma, incision site hemorrhage, peripheral edema, and decreased hemoglobin. Retroperitoneal or Intra-Abdominal Surgery Among 135 subjects undergoing retroperitoneal and intra-abdominal surgery (67 subjects treated with EVICEL ® and 68 controls), one subject experienced an abdominal abscess in the EVICEL ® group. In the control group, one subject experienced an abdominal abscess and one subject experienced a pelvic abscess. Liver Surgery In a controlled study involving 121 subjects undergoing liver surgery (58 treated with EVICEL ® and 63 controls), no adverse reactions were observed. Table 4 provides the adverse reactions of EVICEL ® from three clinical trials. A total of 200 subjects were exposed to EVICEL ® from these studies. Table 4: Frequency of Adverse Reactions from Clinical Trials System organ class Adverse Reactions EVICEL N=200 GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Total 1 PERIPHERAL EDEMA 1 INFECTIONS AND INFESTATIONS Total 4 ABDOMINAL ABSCESS 1 GRAFT INFECTION 2 STAPHYLOCOCCAL INFECTION 1 INJURY, POISONING AND PROCEDURAL COMPLICATIONS Total 6 INCISION SITE HEMORRHAGE 1 INCISION SITE HEMATOMA 1 POST PROCEDURAL HEMATOMA 1 POSTOPERATIVE WOUND COMPLICATION 1 VASCULAR GRAFT OCCLUSION 1 POSTOPERATIVE WOUND INFECTION 1 INVESTIGATIONS Total 1 DECREASED HEMOGLOBIN 1 VASCULAR DISORDERS Total 1 HEMATOMA 1 6.2 Postmarketing Experience The following adverse reactions are reported voluntarily from a population of uncertain size, therefore, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure. Postmarketing fatalities attributable to air or gas embolism have been reported with the use of EVICEL ® when applied using a spray device. These cases have occurred where EVICEL ® was sprayed at a pressure higher than indicated for the device in use and when the spray tip was placed closer than the specified distance from the target site. The following adverse reactions have been reported in postmarketing experience with EVICEL ® in order of decreasing frequency (Table 5): Table 5: Adverse Reactions Postmarketing Experience MedDRA System Organ Class Adverse Reactions GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS PYREXIA INJURY, POISONING AND PROCEDURAL COMPLICATIONS SEROMA CARDIAC DISORDERS CARDIAC ARREST TACHYCARDIA RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PULMONARY EMBOLISM DYSPNEA SKIN AND SUBCUTANEOUS TISSUE DISORDERS URTICARIA
adverse reactions table
<table width="75%" ID="table4"><caption>Table 4: Frequency of Adverse Reactions from Clinical Trials</caption><col width="40%" valign="top" align="left"/><col width="50%" valign="top" align="left"/><col width="10%" valign="top" align="center"/><thead><tr><th align="center" styleCode="Lrule Rrule" valign="bottom">System organ class</th><th align="center" styleCode="Rrule" valign="bottom">Adverse Reactions</th><th styleCode="Rrule">EVICEL N=200 </th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</td><td styleCode="Rrule">Total</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">PERIPHERAL EDEMA</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">INFECTIONS AND INFESTATIONS</td><td styleCode="Rrule">Total</td><td styleCode="Rrule">4</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">ABDOMINAL ABSCESS</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">GRAFT INFECTION</td><td styleCode="Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">STAPHYLOCOCCAL INFECTION</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">INJURY, POISONING AND PROCEDURAL COMPLICATIONS</td><td styleCode="Rrule">Total</td><td styleCode="Rrule">6</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">INCISION SITE HEMORRHAGE</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">INCISION SITE HEMATOMA</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">POST PROCEDURAL HEMATOMA</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">POSTOPERATIVE WOUND COMPLICATION</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">VASCULAR GRAFT OCCLUSION</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">POSTOPERATIVE WOUND INFECTION</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">INVESTIGATIONS</td><td styleCode="Rrule">Total</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">DECREASED HEMOGLOBIN</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">VASCULAR DISORDERS</td><td styleCode="Rrule">Total</td><td styleCode="Rrule">1</td></tr><tr><td styleCode="Lrule Rrule"/><td styleCode="Rrule">HEMATOMA</td><td styleCode="Rrule">1</td></tr></tbody></table>
adverse reactions table
<table width="70%" ID="table5"><caption>Table 5: Adverse Reactions Postmarketing Experience</caption><col width="60%" valign="top" align="left"/><col width="40%" valign="top" align="left"/><thead><tr><th styleCode="Lrule Rrule">MedDRA System Organ Class</th><th styleCode="Rrule">Adverse Reactions</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</td><td styleCode="Rrule">PYREXIA</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">INJURY, POISONING AND PROCEDURAL COMPLICATIONS</td><td styleCode="Rrule">SEROMA</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">CARDIAC DISORDERS</td><td styleCode="Rrule">CARDIAC ARREST</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">TACHYCARDIA</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</td><td styleCode="Rrule">PULMONARY EMBOLISM</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">DYSPNEA</td></tr><tr><td styleCode="Lrule Rrule">SKIN AND SUBCUTANEOUS TISSUE DISORDERS</td><td styleCode="Rrule">URTICARIA</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.